Shire was founded in the year 1986. The company has been operational for almost 133 years now. As of the year 2019, the company is not functional. The founders of the company were Peter Moriarty, Dennis Stephens, Harry Stratford, Geoff Hall and Dr Jim Murray. The company, under the management of Rolf Stahel Shire, was first listed on the London Stock Exchange, in the year 1996. The company's first products were mainly calcium supplements (Calcichew-D3) for patients seeking to treat or even prevent osteoporosis as well. In the year 1997, the company had acquired Pharmavene for 105 million UK Pounds, in order to access Pharmavene's drug delivery methods. In the same year, the company had also acquired Richwood Pharmaceutical Company, forming Shire-Richwood Incorporated.
In the year 2001, the company had acquired Biochem Canada. The company's next acquisition didn't come until 2005 when it had acquired Transkaryotic Therapeutics, and two years later, in the year 2007, the company had taken over New River Pharmaceuticals company for a record amount of $2.6 billion. With the purchase of New River, the company had gained access and also ownership of Vyvanse. A year later, the had company taken over the German company known as Jerini, for almost $521 million. Jerini was mainly focused on treating hereditary angioedema as well. In the year 2008, in the reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company had moved its tax domicile to Dublin, Ireland. The year 2010 had seen a significant change in company strategy, with the company seeking to expand through various mergers and acquisitions - culminating in the company becoming one of the most acquisitive in the industry as well. In the year 2010, the company had acquired Movetis - which was a Belgian company focusing on gastrointestinal products for almost $565 million. A year later the company again acquired regenerative medicine manufacturer, known as Advanced BioHealing. In the year 2012, the company had acquired Ferrokin Biosciences for almost $325 million. Then in the year 2015, NPS Pharmaceuticals was purchased for $5.2 billion, bringing along its rare disease drugs Gattex and Natpara as well. The company had also acquired, later in the same year, Meritage Pharma for $245 million, Foresight Biotherapeutics for $300 million and also Dyax for almost $6.5 billion. As of the year 2018, the company had agreed to sell its oncology business to French pharmaceutical company Servier for 1.7billion UK Pounds. Finally, in the year 2018, an agreement was finally reached in which the company was sold to Takeda in a $62 billion deal. The headquarters of the company is based in 5 Riverwalk, Citywest Business Campus. The name of the place is Dublin 24, while the name of the country is Ireland.
Shire is a company that is based in Ireland and is focused on the research and development of various kinds of biotechnological science drugs and medicines in order to serve people with rare diseases. The current CEO of the company is Flemming Ornskov. As of the year 2017, the total revenue generated by the company is more than $2,455 million. The total number of employees working at the company is more than 22,000, as of the year 2017.
The primary services provided by the company include the research and development of various kinds of biotechnological drugs that are available over 100 countries worldwide. The company serves diseases like haematology, immunology, lysosomal storage disorders, hereditary angioedema, neuroscience, etcetera.
Please log in again. The login page will open in a new window. After logging in you can close it and return to this page.